参考文献 [1] D. Yue, et al. Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE...
参考文献 [1] D. Yue, et al. Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial. 2023 ESMO LBA58. [2] Tina Cascone, et al. CheckMate 77...
followed by surgery and adjuvant tislelizumab led to a significant improvement in event-free survival (EFS) vs neoadjuvant placebo plus PtDb followed by surgery and adjuvant placebo in resectable non–small cell lung cancer (NSCLC), according to data from the phase 3 RATIONALE-...
参考文献 [1]Dongsheng Yue,et al. LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage Ⅱ-ⅢA NSCLC patients (pts) in the phase Ⅲ (Ph3) RATIONALE-315 trial. 2023 ESMO. [2]郑荣寿, 张思维, 孙可欣, 等. 201...
Clinical trial identification NCT04379635. Editorial acknowledgement Medical writing support, under the direction of the authors, was provided by Apurva Davé, PhD, of Medical Expressions, an Inizio company, and was funded by BeiGene, Ltd. Legal entity responsible for the study BeiGene, Ltd. Fundi...
替雷丽珠单抗是一种抗PD-1抗体,经过特殊设计,可最大程度地减少FcɣR巨噬细胞与废除抗体依赖性吞噬作用的结合。与单纯化疗相比,替雷丽珠单抗联合化疗可改善晚期非鳞状细胞肺癌(nsq-NSCLC)患者的临床预后。 Methods 方法 In this open...
[1] Dongsheng Yue,et al. LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage Ⅱ-ⅢA NSCLC patients (pts) in the phase Ⅲ (Ph3) RATIONALE-315 trial. 2023 ESMO. ...